Related Experiment Video
Updated: Jul 6, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
[Neuromidin in the treatment of vascular cognitive disorders]
Abstract:
Neuromidin (ipidacrin) was administered to 41 patients, aged 51-79 years, with mild cognitive impairment (MSI) (19) and vascular dementia (22). The drug was prescribed in increasing dosages from 10 to 40 mg during 6 months (a dosage of 40 mg was administered from the 4th week of the treatment). Cognitive functioning was assessed using some clinical scales (CGI, MMSE, GDS etc) and common neuropsychological tests at the base-line and on the 3rd and 6th month of the treatment. A statistically significant therapeutic effect of neuromidin was revealed in both types of cognitive disorders, with the maximal improvement on the first 3 months and further maintenance of the effect. The most distinct dynamics was observed for memory, attention, abstract reasoning, constructive abilities and general mental activity. The drug was well tolerated.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Treatment
Diabetic Neuropathy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Atherosclerosis III: Management
